A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
Latest Information Update: 24 Feb 2026
At a glance
- Drugs Resiquimod-hydrogel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Surge Therapeutics
Most Recent Events
- 19 Feb 2026 Planned End Date changed from 1 Mar 2026 to 1 Dec 2026.
- 12 Feb 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Sep 2026.
- 25 May 2025 Status changed from not yet recruiting to recruiting.